{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T18:23:11Z","timestamp":1772475791754,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.critrevonc.2019.01.002","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T06:20:16Z","timestamp":1549002016000},"page":"64-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Role of intraperitoneal chemotherapy in ovarian cancer in the platinum-taxane-based era: A meta-analysis"],"prefix":"10.1016","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7098-8956","authenticated-orcid":false,"given":"Claudia","family":"Marchetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5119-8358","authenticated-orcid":false,"given":"Francesca","family":"De Felice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Perniola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Innocenza","family":"Palaia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Musella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violante","family":"Di Donato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Cascialli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovico","family":"Muzii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Tombolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Benedetti Panici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.critrevonc.2019.01.002_bib0005","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.01.002_bib0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2019.01.002_bib0015","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/IGC.0b013e31825736b2","article-title":"Intraperitoneal chemotherapy by ultrasound-guided direct puncture in recurrent ovarian cancer: feasibility, compliance, and complications","volume":"22","author":"Benedetti-Panici","year":"2012","journal-title":"Int. J. Gynecol Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2019.01.002_bib0020","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.01.002_bib0025","unstructured":"Cancer Therapy Evaluation Program. Common terminology criteria for adverse events. Available at: http:\/\/ctep.cancer.gov."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.01.002_bib0030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/gyno.1999.5677","article-title":"Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest","volume":"76","author":"Gadducci","year":"2000","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2019.01.002_bib0035","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.critrevonc.2019.01.002_bib0040","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2019.01.002_bib0045","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005340.pub3","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer","volume":"11","author":"Jaaback","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.01.002_bib0050","first-page":"CD005340","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer","author":"Jaaback","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.critrevonc.2019.01.002_bib0055","unstructured":"http:\/\/www.jgog.gr.jp\/clinical_trial."},{"issue":"4","key":"10.1016\/j.critrevonc.2019.01.002_bib0060","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/annonc\/mdx011","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions","volume":"28","author":"Karam","year":"2017","journal-title":"Ann. Oncol."},{"issue":"9990","key":"10.1016\/j.critrevonc.2019.01.002_bib0065","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.critrevonc.2019.01.002_bib0070","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1006\/gyno.1994.1220","article-title":"A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer","volume":"54","author":"Kirmani","year":"1994","journal-title":"Gynecol. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2019.01.002_bib0075","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","article-title":"Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer","volume":"28","author":"Konstantinopoulos","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.002_bib0080","series-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011)","article-title":"Chapter 6: Searching for studies","author":"Lefebvre","year":"2011"},{"issue":"6","key":"10.1016\/j.critrevonc.2019.01.002_bib0085","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/bjc.2013.70","article-title":"BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study","volume":"108","author":"Lesnock","year":"2013","journal-title":"Br. J Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2019.01.002_bib0090","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2019.01.002_bib0095","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"issue":"Suppl_8","key":"10.1016\/j.critrevonc.2019.01.002_bib0100","doi-asserted-by":"crossref","first-page":"viii40","DOI":"10.1093\/annonc\/mdx451","article-title":"Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?","volume":"28","author":"Monk","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.002_bib0105","unstructured":"National Comprehensive Cancer Network (NCCN), 2018. Guidelines Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer, Version 2. Available at http:\/\/www.nccn.org."},{"key":"10.1016\/j.critrevonc.2019.01.002_bib0110","unstructured":"National Cancer Institute. Bevacizumab and intravenous or intraperitoneal chemotherapy in treating patients with stage II, stage III, or stage IV ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Available at: http:\/\/www.clinicaltrials.gov\/NCT00951496."},{"issue":"4","key":"10.1016\/j.critrevonc.2019.01.002_bib0115","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000011980","article-title":"A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer","volume":"56","author":"Polyzos","year":"1999","journal-title":"Oncology"},{"issue":"2","key":"10.1016\/j.critrevonc.2019.01.002_bib0120","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/annonc\/mdx754","article-title":"OV21\/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer","volume":"29","author":"Provencher","year":"2018","journal-title":"Ann. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2019.01.002_bib0125","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.002_bib0130","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.002_bib0135","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"10","key":"10.1016\/j.critrevonc.2019.01.002_bib0140","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.01.002_bib0145","article-title":"A phase III trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and peritoneal carcinoma: an NRG Oncology study","author":"Walker","year":"2016","journal-title":"ASCO Annual Meeting"},{"issue":"1","key":"10.1016\/j.critrevonc.2019.01.002_bib0150","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0020-7292(00)00340-4","article-title":"Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer","volume":"72","author":"Yen","year":"2001","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"3","key":"10.1016\/j.critrevonc.2019.01.002_bib0155","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ygyno.2009.05.034","article-title":"Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer","volume":"114","author":"Yen","year":"2009","journal-title":"Gynecol. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818305596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818305596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:28:06Z","timestamp":1760902086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842818305596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":31,"alternative-id":["S1040842818305596"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.01.002","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of intraperitoneal chemotherapy in ovarian cancer in the platinum-taxane-based era: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}